Narcolepsy Drug Market

Market Definition

The global Narcolepsy Drug Market size was valued at USD 2.65 billion in 2019, and is predicted to reach USD 6.48 billion by 2030 with a CAGR of 8.4% from 2020-2030.

Narcolepsy is an orphan disease causing a long-term neurological disorder resulting into decreased ability in regulating sleep-wake cycles. The loss of brain-chemical called hypocretins (orexins) causes narcolepsy. Its symptoms are excessive daytime sleepiness, sleep attacks, disrupted night-time sleep, and in some cases, cataplexy, hallucinations, and/or sleep paralysis are observed.

Market Dynamics and Trends

The global Narcolepsy drug market observes a substantial growth and is expected to grow at a considerable rate throughout the forecast period. Higher prevalence of sleep disorders resulting from high stress levels, unhealthy lifestyles, as well as increased consumption of alcohol, coffee, and tobacco, are anticipated to supplement the growth of narcolepsy drug market.

Furthermore, factors such as advancements in healthcare infrastructures, ongoing R&D activities, and rise in per-capita disposable incomes, are expected to propel the growth of narcolepsy drug market throughout the forecast period.

According to Narcolepsy Network, 60% of patients were misdiagnosed of Narcolepsy, and only 25% people suffering from narcolepsy have been diagnosed and are undergoing proper treatment. Hence, the lack of awareness regarding proper diagnosis and treatment availability, are the limiting factors hampering the growth of global narcolepsy drug market.

Moreover, increase in initiatives by government and non-government organizations in spreading awareness about this rare disease, and favorable reimbursement policies for FDA-approved prescribed medicines, shall create lucrative opportunities in the global narcolepsy drug market.

Market Segmentations and Scope of the Study:

The global narcolepsy drug market share has been analyzed based on disease type, diagnosis, drug type, and geography.

Based on disease type, the market is segmented into narcolepsy type I and narcolepsy type II. Based on diagnosis, the market is divided into Polysomnogram, and Multiple Sleep Latency Test. Based on the type of drug, the market is fragmented into Tricyclic Antidepressants, Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate, and others. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America represents high prevalence rate of sleep disorders due to unhealthy lifestyles as well as increased consumption of alcohol and tobacco. Furthermore, the increase in research and development activities, constant increase in FDA approval of drugs, and developed healthcare infrastructure are supplementing the growth of the narcolepsy drug market.

It is expected that the emerging economies, specifically in the Asia-Pacific region would witness increasing market size owing to fast developing healthcare facilities in this region. Additionally, increasing awareness about sleep disorders, and growing adoption of narcolepsy drugs, are further expected to augment the growth of narcolepsy drug market over the forecast period.

Competitive Landscape

The narcolepsy drug market, is consolidated as it has few major players such as Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Shire Plc, Addrenex Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, Ligand Pharmaceuticals, and Graymark Healthcare, Inc. among others. The global narcolepsy drug market is gaining momentum due to an upsurge in R&D activities and proliferating number of drugs manufactured by key players, which are achieving FDA approval.

For instance, In February 2019, Harmony Biosciences LLC., a leading company in narcolepsy drug market, announced that the FDA has accepted for filing the NDA for its investigational product, ‘PITOLISANT’, a highly selective histamine-3 (antagonist/inverse agonist receptor); and has granted Priority Review for this NDA. In patients suffering from narcolepsy, PITOLISANT offers treatment options for both excessive daytime sleepiness and cataplexy.

In September 2019, at the World Sleep Congress, research data presented by Takeda Pharmaceutical Company Limited, a leading manufacturer in narcolepsy drug market demonstrated that ‘TAK-925’, a selective Orexin Type-2 Receptor (OX2R) Agonist, showed early signs of effectiveness in the patients suffering from narcolepsy type-1. The studies also evaluated tolerability, safety, pharmacodynamic and pharmacokinetic effects of TAK-925.

Furthermore, in March 2020, Jazz Pharmaceuticals, one of the major players in narcolepsy drug market, announced that the FDA has accepted for filing the NDA with priority review for its ‘JZP-258,’ a novel oxybate-product candidate with unique cation composition, used for the treatment of both excessive daytime sleepiness and cataplexy in patients ageing 7 years and above.

KEY BENEFITS

• The narcolepsy drug market report provides the quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises a deep dive analysis of the narcolepsy drug market trend including the current and future trends for depicting the prevalent investment pockets in the market.

• The report provides detailed information related to key drivers, restraints, opportunities, and their impact on the narcolepsy drug market.

• The report incorporates competitive analysis of the market players along with their market share in the global narcolepsy drug market.

• The SWOT analysis and Porters Five Forces model is elaborated in the study of the narcolepsy drug market.

• Value chain analysis in the narcolepsy drug market study provides a clear picture of the stakeholders’ roles.

KEY MARKET SEGMENTS:

By Disease Type

• Narcolepsy Type I

• Narcolepsy Type II

By Diagnosis

• Polysomnogram

• Multiple Sleep Latency Test

By Drug Type

• Central Nervous System Stimulants

• Tricyclic Antidepressants

• Sodium Oxybate

• Selective Serotonin Reuptake Inhibitor

• Others

By Geography

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Rest of Europe

• Asia-Pacific

  • China

  • India

  • Japan

  • Australia

  • Rest of Asia-Pacific

• RoW

  • UAE

  • Saudi Arabia

  • South Africa

  • Brazil

  • Remaining Countries

KEY PLAYERS:

• Addrenex Pharmaceuticals
• Arena Pharmaceuticals
• Shire Plc
• Teva Pharmaceutical Industries Ltd.
• Bioprojet
• Ligand Pharmaceuticals
• Jazz Pharmaceuticals Plc.
• Graymark Healthcare, Inc.

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Analysis Period	2019–2030
Base Year Considered	2020
Forecast Period	2020–2030
Market Size Estimation	Billion (USD)
Market Segmentation	By Disease Type (Narcolepsy type I and Narcolepsy type II), by Diagnosis (Polysomnogram and Multiple Sleep Latency Test), By Drug Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (UK, Germany, Italy, France, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of APAC), Rest of the World (UAE, Saudi Arabia, South Africa, Brazil, Remaining countries)
Companies Profiled	Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Shire Plc, Addrenex Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, Ligand Pharmaceuticals, and Graymark Healthcare, Inc.